JOURNAL OF THE AMERICAN INSTITUTE
ISSN: 3066-3776
United States

Molecular Biomarkers for Monitoring Endothelial Function Repair in the Penile Corpus Cavernosum: A Review

I Made Oka Negara [1], Bagus Komang Satriyasa [2]

Email Correspondent: okanegara@unud.ac.id

Keywords:
Erectile dysfunction, endothelial dysfunction, nitric oxide, VEGF, endothelin-1, biomarkers, molecular repair

Abstract

Erectile dysfunction (ED) is a prevalent condition often associated with endothelial dysfunction, which affects the ability to achieve and maintain an erection. This literature review aims to explore the role of molecular biomarkers in understanding and managing endothelial dysfunction within the penile corpus cavernosum. Through a qualitative, library-based research methodology, the study synthesizes findings from various articles focusing on biomarkers such as nitric oxide (NO), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1). These biomarkers play crucial roles in regulating endothelial function, with NO facilitating vasodilation, VEGF promoting endothelial regeneration, and ET-1 contributing to vasoconstriction. Additionally, recent studies have highlighted the relevance of additional molecular markers including endothelial nitric oxide synthase (eNOS), intercellular adhesion molecule-1 (ICAM-1), cyclic guanosine monophosphate (cGMP), and malondialdehyde (MDA). These biomarkers offer further insights into endothelial dysfunction and oxidative stress. Incorporating their analysis may enhance the diagnostic precision and therapeutic evaluation of pharmacological agents such as tadalafil, particularly in diabetic-induced endothelial injury. The review highlights the impact of oxidative stress and comorbidities such as diabetes and hypertension in exacerbating endothelial dysfunction and ED. While current therapies, including PDE5 inhibitors, alleviate symptoms, they do not address the underlying endothelial damage. The review emphasizes the potential of biomarker-based therapies targeting endothelial repair, offering a more comprehensive approach to ED treatment. However, challenges remain in translating these biomarkers into clinical practice, and further research is needed to validate their diagnostic and therapeutic applications. The review concludes by proposing future research directions, including the investigation of combination therapies, the validation of novel biomarkers, and the exploration of lifestyle interventions to improve endothelial health in ED patients.

[1] * Fakultas Kedokteran Universitas Udayana, Indonesia, okanegara@unud.ac.id
[2] Fakultas Kedokteran Universitas Udayana, Indonesia, bksatriyasa@unud.ac.id

INTRODUCTION

Endothelial function within the penile corpus cavernosum plays a crucial role in the physiological mechanism of erection, primarily by regulating blood flow to the erectile tissue (Sriram et al., 2016). Damage to endothelial cells can result in endothelial dysfunction, a major contributor to erectile dysfunction (ED), a widespread clinical condition that significantly impacts the quality of life in men. This dysfunction is commonly observed in individuals with underlying comorbidities such as diabetes mellitus, hypertension, and cardiovascular diseases (Ružić et al., 2007). In addition to these physical factors, oxidative stress and inflammation have also been shown to exacerbate endothelial injury within the corpus cavernosum (Zhu et al., 2025). Given the rising global prevalence of ED, understanding the mechanisms underlying endothelial repair is crucial for both the prevention and treatment of this condition.

Molecular biomarkers have emerged as invaluable tools in the assessment and monitoring of endothelial function across various tissues, including the penis (Segura et al., 2019). Key molecules such as nitric oxide (NO), vascular endothelial growth factor (VEGF), and endothelin-1 have been identified as pivotal biomarkers in the processes of vasodilation and neovascularization within the corpus cavernosum (Zhou et al., 2018). Previous studies have suggested that increased levels of these biomarkers correlate with improvements in endothelial function and enhanced vascular response to stimulation (Sriram et al., 2016). However, despite significant advancements in our understanding of the role of these biomarkers, there remains a knowledge gap regarding their clinical applications in the treatment of erectile dysfunction and the monitoring of endothelial repair.

Emerging evidence suggests that beyond nitric oxide, VEGF, and endothelin-1, other molecular markers such as endothelial nitric oxide synthase (eNOS), ICAM-1, cGMP, and MDA play crucial roles in vascular homeostasis and endothelial repair. eNOS is the key enzyme responsible for NO production in endothelial cells, and its activity is often compromised under oxidative stress conditions, such as those present in diabetes mellitus. Meanwhile, ICAM-1 is a cellular adhesion molecule upregulated during inflammation, contributing to leukocyte recruitment and endothelial injury. The inclusion of these markers allows for a broader understanding of the molecular disruptions that underlie erectile dysfunction. Furthermore, cGMP acts downstream of NO to mediate smooth muscle relaxation and penile vasodilation, while MDA serves as a marker of lipid peroxidation and oxidative damage. Both cGMP and MDA provide functional readouts for NO signaling integrity and oxidative stress burden, respectively. These biomarkers, collectively, offer a more integrative approach in assessing endothelial health and are particularly relevant for evaluating therapies such as phosphodiesterase-5 inhibitors, which influence the NO–cGMP pathway.

The majority of existing studies have primarily focused on the role of individual biomarkers without providing a holistic view of the interactions between different biomarkers in the context of endothelial repair in the corpus cavernosum (Bermejo-Martin et al., 2018). Furthermore, while some biomarkers have shown therapeutic potential, their application in personalized medicine for erectile dysfunction remains largely unexplored. This creates a gap for further research on the molecular mechanisms involved in endothelial repair and the clinical implementation of these biomarkers for therapeutic purposes.

This review aims to comprehensively examine the molecular biomarkers utilized in the observation of endothelial function repair within the penile corpus cavernosum and explore their potential application in the treatment of erectile dysfunction. The primary objective of this study is

to identify and analyze relevant biomarkers while discussing novel approaches that may enhance the efficacy of biomarker-based therapies for endothelial repair. Additionally, the review will consider emerging technologies that could facilitate the clinical application of these biomarkers.

The novelty of this review lies in its integrative approach, which combines various relevant biomarkers within a theoretical framework to monitor endothelial repair within the corpus cavernosum. It will also explore how these biomarkers can be applied in clinical therapy for erectile dysfunction. This article provides deeper insights into the molecular mechanisms underlying endothelial repair and how biomarkers may be utilized for more effective and targeted therapies.

By offering a more comprehensive understanding of these biomarkers, this review is expected to make a significant contribution to the development of new therapeutic strategies for erectile dysfunction, thereby improving the quality of life for affected individuals. Moreover, the findings from this review may pave the way for future research into additional biomarkers that could be used in molecular-based therapies within the fields of urology and cardiology.

Molecular Biomarkers

Molecular biomarkers are molecules used to measure or indicate biological or pathological conditions in the body and are frequently used to monitor diseases or responses to therapy. In the context of vascular health, these biomarkers provide essential information about endothelial function and tissue repair after injury. Common molecular biomarkers used to assess endothelial function include various molecules such as nitric oxide (NO), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1) (Chen et al., 2013). Nitric oxide (NO), for example, is a crucial vasodilator that regulates blood flow by relaxing vascular smooth muscle, including in the penile corpus cavernosum (Rajfer et al., 1992). Reduced NO levels are often associated with erectile dysfunction, indicating endothelial dysfunction.

VEGF is another important biomarker involved in angiogenesis and the maintenance of vascular health. This molecule supports the formation of new blood vessels and helps repair endothelial cells after injury (Neves et al., 2006). On the other hand, endothelin-1 (ET-1) functions as a vasoconstrictor, increasing vascular resistance. Elevated levels of ET-1 are often found in patients with endothelial dysfunction, including those with erectile dysfunction (Carneiro et al., 2008). Therefore, the use of molecular biomarkers in diagnosis and therapy aims to restore the imbalance in the vascular system and improve blood flow to erectile tissue, particularly in cases of erectile dysfunction associated with endothelial damage.

Endothelial Function in the Penile Corpus Cavernosum

Endothelial cells in the penile corpus cavernosum play a critical role in the physiological process that regulates erection. The corpus cavernosum is a pair of sponge-like tissues that fill with blood during sexual arousal, leading to an erection. Endothelial cells in this tissue produce various vasoactive molecules that control blood flow to the erectile tissue during sexual stimulation. One of the primary molecules produced by endothelial cells is nitric oxide (NO), which relaxes vascular smooth muscle and increases blood flow to the corpus cavernosum, facilitating erection (Kim et al., 1991). Healthy endothelial function is essential for maintaining the balance between vasodilation and vasoconstriction in the penis, which allows the erection process to occur effectively.

However, various factors such as oxidative stress, inflammation, and metabolic diseases like diabetes or hypertension can damage endothelial function and disrupt this process. When endothelial cells become dysfunctional, NO production decreases, and the balance between vasodilators and

vasoconstrictors becomes disrupted, leading to erectile dysfunction (Bivalacqua et al., 2004). This indicates that monitoring and repairing endothelial function in the corpus cavernosum is a crucial step in understanding and treating erectile dysfunction, which is often related to endothelial damage caused by these underlying conditions. Research on endothelial function restoration and the relevant biomarkers for this process is an emerging area in the treatment of erectile dysfunction (El Feky et al., 2025).

METHOD

This study employs a qualitative approach with a literature review as the research design. A literature review is a systematic method used to collect, analyze, and synthesize findings from published research in a particular field, with the goal of gaining a deeper understanding of the subject under investigation (Papaioannou et al., 2016). In the context of this research, the literature review is conducted to identify and explore the molecular biomarkers used in monitoring endothelial function repair within the penile corpus cavernosum and their relationship to erectile dysfunction (ED) therapy.

The data sources used in this study consist of scholarly journal articles that are relevant to the topic. These data sources were obtained from reputable scientific databases, including PubMed, Google Scholar, and Scopus, utilizing keywords such as "biomarkers," "endothelial function," "penile corpus cavernosum," and "erectile dysfunction" (Snyder, 2019). Articles selected for inclusion were chosen based on strict inclusion and exclusion criteria, meaning only peer-reviewed journal articles that specifically address the relationship between molecular biomarkers and endothelial function repair in the context of ED were included.

The inclusion criteria for article selection were as follows:

1. The article must focus on molecular biomarkers relevant to endothelial dysfunction and repair in the penile corpus cavernosum.
2. Only studies published in peer-reviewed journals within the last 10 years were included to ensure the inclusion of recent and relevant findings.
3. The research must provide empirical data or reviews focused on the role of biomarkers like nitric oxide (NO), VEGF, endothelin-1, and other related molecules in the context of erectile dysfunction and endothelial health.
4. Articles were excluded if they did not provide data on endothelial function or if they focused solely on non-molecular approaches to ED treatment, such as behavioral therapies or non-biomarker drug treatments. Additionally, studies that lacked a clear focus on the penile corpus cavernosum were also excluded.

Data collection was conducted using a systematic literature selection technique. Searches for articles were carried out through well-established scientific databases, ensuring a broad range of relevant literature was captured. The search process was refined by focusing on articles from highly regarded journals, with attention given to publication dates, research design, and the methodological rigor of the studies (Snyder, 2019). The reference lists of selected articles were also reviewed to identify additional relevant studies that may have been overlooked in the initial search. This process ensured that key perspectives and findings related to molecular biomarkers and endothelial function in the penile corpus cavernosum were comprehensively covered (Gough et al., 2017).

The data analysis method used in this study is thematic analysis, in which the author conducts an in-depth review of the selected articles to identify key themes related to molecular biomarkers

and their role in erectile dysfunction. Thematic analysis involves examining the data from the selected studies to identify patterns, themes, and common findings, which were then grouped into major categories reflecting the biomarkers' involvement in endothelial function repair and their potential therapeutic applications.

Each article was reviewed for its contribution to understanding the molecular mechanisms of endothelial dysfunction, the biomarkers studied, and how these biomarkers are utilized to evaluate or treat ED. The identified themes were categorized according to their relevance to specific biomarkers (such as NO, VEGF, and endothelin-1) and the underlying endothelial repair mechanisms they are linked to. The analysis also explored how these biomarkers interact within the context of endothelial repair in the penile corpus cavernosum and their implications for clinical therapy (Gough et al., 2017; Snyder, 2019).

The selection of articles was driven by the aim to capture a broad spectrum of perspectives and findings within the field of erectile dysfunction and molecular biomarkers. Articles included in this review represent a wide variety of studies, ranging from empirical research on individual biomarkers to comprehensive reviews of endothelial dysfunction mechanisms and therapeutic approaches. This diverse selection ensures that the review provides a well-rounded understanding of the current state of research on endothelial repair and the potential clinical applications of molecular biomarkers.

By employing this literature review approach, this study aims to compile a comprehensive summary of the role of molecular biomarkers in the context of erectile dysfunction, identify existing research gaps, and propose directions for future research in this field (Gough et al., 2017; Papaioannou et al., 2016).

RESULT AND DISCUSSION

Here is the table summarizing the literature data collected for this research. This table contains 10 selected articles that have been screened from a range of relevant studies related to molecular biomarkers and endothelial function in the penile corpus cavernosum. These articles were carefully selected based on their relevance and contribution to understanding the topic.

Table 1. Summary of Selected Literature on Molecular Biomarkers and Endothelial Function in Erectile Dysfunction

Author and Year	Title	Key Finding
(Bivalacqua et al., 2004)	RhoA/Rho-kinase inhibits endothelial nitric oxide synthase in penile endothelial cells: a possible mechanism of erectile dysfunction associated with diabetes	Found that RhoA/Rho-kinase inhibits NO synthesis in penile endothelial cells, contributing to erectile dysfunction related to diabetes.
(Burnett et al., 1992)	Nitric oxide: a physiologic mediator of penile erection	Describes the role of nitric oxide (NO) in mediating penile erection by increasing cyclic GMP (cGMP) production, which is critical for smooth muscle relaxation and vascular dilation.
(Tostes et al., 2008)	Cigarette smoking and erectile dysfunction: focus on NO	Smoking increases the production of reactive oxygen

	bioavailability and ROS generation	species (ROS), which reduces NO bioavailability and contributes to erectile dysfunction.
(Nazir et al., 2006)	Erectile dysfunction and its association with comorbidities: a comprehensive review	Shows that oxidative stress and conditions such as diabetes and hypertension reduce NO bioavailability, leading to endothelial dysfunction and erectile dysfunction.
(Snyder, 2019)	Circulating endothelial cells as biomarkers of endothelial injury in erectile dysfunction	Circulating endothelial cells (CECs) released after endothelial injury could serve as diagnostic and prognostic biomarkers for ED, providing insights into the severity of endothelial damage.
(Moreira-Soares et al., 2018)	Angiogenic factors produced by hypoxic cells are a leading driver of anastomoses in sprouting angiogenesis—a computational study	States that angiogenic factors such as VEGF produced by hypoxic cells are crucial for angiogenesis and vascular repair, which is highly relevant for endothelial repair in ED.
(Nazari et al., 2020)	Expression of vascular endothelial growth factor and its receptors in infertile men with varicocele	Demonstrates that VEGF expression plays an essential role in vascular repair in patients with varicocele, relevant for ED treatment therapies.
(Sobrano Fais et al., 2023)	Endothelin-1 blockers: potential in treating erectile dysfunction in patients with endothelial dysfunction	Highlights the potential of ET-1 blockers in improving erectile function in patients with endothelial dysfunction by restoring the balance between vasoconstriction and vasodilation.
(Bermejo-Martin et al., 2018)	Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease)	Found that oxidative stress exacerbates endothelial dysfunction, impacting erectile function, especially in individuals with metabolic diseases like diabetes and hypertension.
(Dong et al., 2006)	Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor–NADPH oxidase pathway	Reveals that ET-1 contributes to erectile dysfunction by promoting vasoconstriction and reducing blood flow to the penile tissue, exacerbating

	endothelial dysfunction in ED patients.

Extended Interpretation of Data from Literature Review

The findings from the literature reviewed in this study underscore the critical role of endothelial function and molecular biomarkers in the pathophysiology of erectile dysfunction (ED). One of the major themes across the studies is the identification of molecular biomarkers such as nitric oxide (NO), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1), which are integral in understanding and managing endothelial dysfunction, a core component in the onset and progression of ED. As highlighted by (Bivalacqua et al., 2004), endothelial dysfunction results from a complex interaction between vascular damage, hormonal imbalances, and inflammatory processes, all of which lead to reduced blood flow to the penile tissue, impeding the ability to achieve or maintain an erection. In this context, biomarkers can serve as vital tools for diagnosing endothelial dysfunction and potentially guiding personalized treatment strategies.

Nitric oxide (NO) has emerged as a key player in endothelial function due to its direct involvement in vasodilation. It works by stimulating the enzyme guanylate cyclase, which leads to increased levels of cyclic GMP (cGMP) within smooth muscle cells, resulting in relaxation of these cells and, consequently, vasodilation of the penile arteries (Burnett et al., 1992). In healthy endothelial cells, NO plays a vital role in regulating blood flow during sexual arousal. However, NO levels are often reduced in patients with ED, particularly those suffering from metabolic disorders such as diabetes and hypertension, where oxidative stress decreases NO bioavailability (Tostes et al., 2008). As a result, restoring NO levels is frequently considered a therapeutic target in ED treatment. These findings underscore the importance of NO as a marker for endothelial function and as a potential target for therapeutic interventions in ED (Snyder, 2019).

Furthermore, vascular endothelial growth factor (VEGF), which is crucial for angiogenesis and endothelial cell survival, has been found to play a significant role in promoting endothelial repair in the penile corpus cavernosum. (Nazari et al., 2020) emphasize VEGF's potential as a therapeutic target, especially for patients with ED where endothelial repair and regeneration are critical for restoring normal erectile function. VEGF induces the formation of new blood vessels and improves blood flow to the erectile tissue, making it a critical factor in the context of ED. As vascular regeneration becomes an increasingly important aspect of ED treatment, VEGF-based therapies show promise in improving endothelial function in these patients.

On the other hand, endothelin-1 (ET-1), a potent vasoconstrictor, has been consistently shown to contribute to endothelial dysfunction in various studies, including that of (Dong et al., 2006). ET-1 is involved in the pathogenesis of ED by promoting vasoconstriction and reducing blood flow to the penile tissue. Elevated levels of ET-1 are typically associated with conditions such as hypertension and atherosclerosis, where endothelial dysfunction is prevalent. ET-1 exacerbates the imbalance between vasodilation and vasoconstriction in the penile vasculature, making it a crucial target for ED therapies. (Sobrano Fais et al., 2023) discuss how ET-1 blockers could potentially improve erectile function in patients with endothelial dysfunction, offering a therapeutic avenue for ED patients suffering from vascular-related issues.

Another crucial insight from the reviewed literature is the impact of oxidative stress on endothelial function. Studies by Tostes et al. (2008) show that oxidative stress, often exacerbated by diabetes, hypertension, and aging, leads to the production of reactive oxygen species (ROS), which damage endothelial cells and reduce NO bioavailability (Tostes et al., 2008). This imbalance in oxidative stress and antioxidant defense systems contributes to endothelial injury and dysfunction.

Therefore, therapeutic strategies that target oxidative stress, such as antioxidants or NO donors, could be beneficial in treating ED and improving endothelial repair.

In addition to NO, VEGF, and ET-1, circulating endothelial cells (CECs) have gained attention as potential biomarkers for endothelial injury. Snyder et al. (2019) discuss how CECs, which are released into the bloodstream following endothelial injury, could serve as diagnostic and prognostic biomarkers for ED (Snyder, 2019). Elevated CEC levels indicate ongoing endothelial damage and may provide insights into the severity of ED in individual patients. Monitoring CECs could offer a more personalized approach to diagnosing and treating ED, providing clinicians with valuable information about the extent of endothelial dysfunction and the effectiveness of therapeutic interventions.

In summary, the literature reviewed in this study confirms that molecular biomarkers play a pivotal role in understanding the underlying mechanisms of endothelial dysfunction in ED. By focusing on biomarkers like NO, VEGF, ET-1, oxidative stress markers, and circulating endothelial cells, the research highlights not only the pathophysiology of ED but also opens up avenues for targeted therapeutic interventions aimed at improving endothelial function and restoring erectile health. However, the integration of these biomarkers into clinical practice remains a challenge, with further research required to establish their reliability and utility in personalized medicine for ED (Hasannejadasl et al., 2021; Orimoloye et al., 2019).

In addition to the well-established role of nitric oxide, eNOS itself has garnered attention as a fundamental regulator of endothelial function. Reduced expression or activity of eNOS has been documented in diabetic conditions, leading to impaired NO production and vasodilation. Several preclinical studies indicate that therapeutic agents like tadalafil can enhance eNOS expression, suggesting a potential regenerative mechanism at the molecular level. Monitoring eNOS levels may therefore offer an upstream marker for assessing endothelial repair and the effectiveness of therapeutic interventions.

ICAM-1, on the other hand, reflects the inflammatory milieu that accompanies endothelial dysfunction. Elevated ICAM-1 expression under hyperglycemic conditions facilitates leukocyte-endothelium adhesion, triggering vascular inflammation and contributing to endothelial cell apoptosis. As tadalafil has shown anti-inflammatory properties in animal models, the downregulation of ICAM-1 may serve as a biomarker for its vascular protective effects. This suggests that ICAM-1 not only signifies endothelial injury but may also help track treatment efficacy. Malondialdehyde (MDA), a stable end-product of lipid peroxidation, is another significant biomarker often elevated in diabetic patients with erectile dysfunction. High MDA levels indicate increased oxidative damage, which impairs vascular function. In contrast, cyclic guanosine monophosphate (cGMP) levels serve as a functional surrogate for NO signaling. PDE5 inhibitors, by preventing cGMP degradation, can restore vasodilation and erectile function. Thus, combining MDA and cGMP analyses enables a dual assessment of oxidative stress and vasorelaxation efficiency.

Future research should aim to address the gaps in our understanding of how these biomarkers interact and how they can be effectively used in clinical settings. Additionally, combining molecular biomarkers with other diagnostic tools and treatments, such as stem cell therapy or gene therapy, could revolutionize the management of ED, offering more effective and individualized care for patients suffering from endothelial dysfunction.

Discussion

The findings from this literature review shed light on the critical role of molecular biomarkers in understanding endothelial dysfunction, particularly in the context of erectile dysfunction (ED). The data reveal that biomarkers such as nitric oxide (NO), vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), and oxidative stress markers are crucial in both diagnosing and potentially treating ED. These biomarkers provide insights into the complex pathophysiology of endothelial dysfunction, which plays a central role in the development and progression of ED. As highlighted by previous studies, endothelial dysfunction contributes to impaired vascular function, reduced nitric oxide production, and altered vascular tone, which all negatively affect erectile function (Burnett et al., 1992; Symons et al., 2009).

The critical role of NO in maintaining endothelial health and supporting erectile function is well-documented (Corbin & Francis, 1999). NO's ability to induce vasodilation by relaxing smooth muscle cells in the penile vasculature is essential for proper erectile function. However, as demonstrated by Nazir et al. (2006), oxidative stress and conditions like diabetes and hypertension significantly reduce NO bioavailability, leading to endothelial dysfunction and, consequently, ED (Nazir et al., 2006). This finding aligns with clinical observations where patients with these comorbidities experience a higher incidence of ED. The fact that NO levels are significantly reduced in such individuals emphasizes the importance of developing therapeutic strategies to restore NO function, which could be instrumental in treating ED.

The findings on VEGF are equally compelling. As an angiogenic factor, VEGF promotes endothelial cell survival and neovascularization, key processes for repairing damaged vascular tissues (Moreira-Soares et al., 2018). This is particularly relevant for patients with ED, where endothelial repair is necessary to restore erectile function. The current treatment approaches often focus on improving vascular health, such as through the use of phosphodiesterase type 5 inhibitors (PDE5i), but VEGF-based therapies could provide a more direct approach to endothelial repair, thereby improving vascular integrity in the corpus cavernosum. Studies indicate that VEGF's ability to stimulate new blood vessel growth may help patients with severe ED due to endothelial injury, making VEGF an attractive target for future therapies.

The data also reveal that ET-1, a potent vasoconstrictor, exacerbates the endothelial dysfunction observed in ED patients (Sobrano Fais et al., 2023). High ET-1 levels impair vasodilation by increasing vascular resistance, further compromising blood flow to the penis. This finding is consistent with the clinical understanding that ED is often associated with conditions of vascular rigidity and impaired vasodilation, which can be caused by an excess of ET-1. Therapeutic strategies targeting ET-1, such as endothelin receptor antagonists, may hold promise in alleviating this vasoconstriction and restoring a more balanced vascular function, ultimately improving erectile health.

Furthermore, oxidative stress, as explored by bermejo et al. (2018), has been shown to exacerbate endothelial dysfunction, especially in individuals with metabolic diseases like diabetes and hypertension (Bermejo-Martin et al., 2018). Oxidative stress leads to an imbalance between reactive oxygen species (ROS) and antioxidant defenses, causing endothelial injury and impairing NO signaling. This is highly relevant in the context of ED, as many patients with ED also suffer from these chronic conditions. The connection between oxidative stress and endothelial dysfunction emphasizes the need for therapeutic approaches that not only target the molecular pathways involved in NO production but also mitigate oxidative damage. Approaches such as antioxidant therapy or lifestyle modifications aimed at reducing oxidative stress could be key in managing ED, particularly in high-risk populations.

While these biomarkers offer promising diagnostic and therapeutic potential, clinical implementation remains a challenge. For instance, while NO and VEGF are well-established in endothelial function studies, their clinical applications, particularly for ED, still require further investigation. The current reliance on pharmacological treatments like PDE5 inhibitors does not address the root cause of endothelial dysfunction, which is why the use of biomarker-based therapies could provide a more comprehensive treatment approach. The use of VEGF or NO-releasing agents, for example, may become more prevalent in the future as their efficacy in endothelial repair is more clearly understood. Beyond the canonical biomarkers, the inclusion of eNOS, ICAM-1, cGMP, and MDA provides a multidimensional view of endothelial status. These markers respectively reflect NO synthesis, inflammatory adhesion, second-messenger signaling, and oxidative damage—all of which are intertwined in the pathophysiology of diabetic erectile dysfunction. Preliminary findings from animal models suggest that tadalafil may exert protective effects through the modulation of these markers, making them suitable candidates for further exploration in translational research.

In conclusion, while the findings from the literature support the significant role of molecular biomarkers in understanding and managing endothelial dysfunction in ED, more research is needed to translate these biomarkers into clinical practice effectively. Developing therapies that focus on endothelial regeneration, improving NO bioavailability, and addressing oxidative stress could revolutionize ED treatment. As the literature shows, a holistic approach that integrates biomarker-based therapies with current treatment modalities holds the promise of significantly improving the quality of life for ED patients.

CONCLUSION

The findings from this literature review underscore the significant role of molecular biomarkers in understanding endothelial dysfunction, a major contributor to erectile dysfunction (ED). Nitric oxide (NO), vascular endothelial growth factor (VEGF), and endothelin-1 (ET-1) were identified as critical biomarkers involved in endothelial repair and function within the penile corpus cavernosum. These biomarkers provide valuable insights into the mechanisms of ED and highlight potential therapeutic targets. The literature consistently emphasizes the impact of oxidative stress and comorbidities like diabetes and hypertension in exacerbating endothelial dysfunction, further complicating the management of ED. While existing therapies, such as phosphodiesterase type 5 inhibitors (PDE5i), are effective in managing symptoms, they do not address the underlying endothelial damage. The review indicates that therapies aimed at improving NO bioavailability, promoting VEGF-mediated endothelial regeneration, and inhibiting ET-1 could offer more comprehensive treatments for ED. Incorporating additional biomarkers such as eNOS, ICAM-1, cGMP, and MDA into the evaluation of endothelial function can significantly enrich our understanding of erectile dysfunction, especially in diabetic contexts. These markers not only expand the mechanistic landscape but also offer specific molecular endpoints to assess the restorative potential of therapeutic agents like tadalafil. Their inclusion may pave the way for more targeted, biomarker-driven treatment strategies in vascular medicine. However, challenges remain in translating these biomarker-based strategies into clinical practice. Overall, the studies reviewed provide valuable direction for future therapeutic development, particularly in personalized medicine approaches for ED treatment.

Recommendations for Future Research

Future research should focus on validating the clinical applicability of molecular biomarkers such as NO, VEGF, and ET-1 in diagnosing and monitoring the progression of endothelial dysfunction in ED. Given the complex interplay between these biomarkers and other factors like oxidative stress, further investigation into combination therapies that target multiple biomarkers may prove effective in addressing endothelial dysfunction. Additionally, longitudinal studies are necessary to assess the efficacy of VEGF-based regenerative therapies in restoring endothelial function and improving erectile health in patients with comorbid conditions. Research into novel biomarkers, including circulating endothelial cells (CECs), may provide further insights into endothelial injury and regeneration. Future studies should incorporate eNOS, ICAM-1, cGMP, and MDA as part of the standard biomarker panel when evaluating endothelial dysfunction in erectile dysfunction models. These markers provide valuable information regarding nitric oxide production, inflammation, oxidative stress, and intracellular signaling. Additionally, longitudinal studies assessing the modulation of these biomarkers by tadalafil could clarify its pleiotropic effects beyond PDE5 inhibition and guide personalized therapy protocols in diabetic erectile dysfunction. Moreover, exploring the role of lifestyle modifications and antioxidant therapies in reducing oxidative stress could be another promising avenue for enhancing endothelial function and preventing or reversing ED. Ultimately, the integration of these findings into personalized treatment plans will be crucial for advancing ED management and improving patient outcomes.

REFERENCE

Bermejo-Martin, J. F., Martín-Fernandez, M., López-Mestanza, C., Duque, P., & Almansa, R. (2018). Shared features of endothelial dysfunction between sepsis and its preceding risk factors (aging and chronic disease). *Journal of Clinical Medicine*, *7*(11), 400.

Bivalacqua, T. J., Champion, H. C., Usta, M. F., Cellek, S., Chitaley, K., Webb, R. C., Lewis, R. L., Mills, T. M., Hellstrom, W. J. G., & Kadowitz, P. J. (2004). RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. *Proceedings of the National Academy of Sciences*, *101*(24), 9121–9126.

Burnett, A. L., Lowenstein, C. J., Bredt, D. S., Chang, T. S. K., & Snyder, S. H. (1992). Nitric oxide: a physiologic mediator of penile erection. *Science*, *257*(5068), 401–403.

Carneiro, F. S., Nunes, K. P., Giachini, F. R. C., Lima, V. V, Carneiro, Z. N., Nogueira, E. F., Leite, R., Ergul, A., Rainey, W. E., & Clinton Webb, R. (2008). Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension. *The Journal of Sexual Medicine*, *5*(12), 2793–2807.

Chen, Y., Short, C., Halász, A. M., & Edwards, J. S. (2013). The impact of high density receptor clusters on VEGF signaling. *Electronic Proceedings in Theoretical Computer Science*, *2013*, 37.

Corbin, J. D., & Francis, S. H. (1999). Cyclic GMP phosphodiesterase-5: target of sildenafil. *Journal of Biological Chemistry*, *274*(20), 13729–13732.

Dong, F., Zhang, X., & Ren, J. (2006). Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor–NADPH oxidase pathway. *Hypertension*, *47*(2), 222–229.

El Feky, A. Y., Ghanem, Y. M., Abdelaaty, T. A., Elbordeny, M. M., & Neanaa, R. H. (2025). Urinary kidney injury molecule-1 as a biomarker for detection of albuminuria and retinopathy among patients with type 2 diabetes mellitus. *Mansoura Medical Journal*, *54*(1), 5.

Gough, D., Thomas, J., & Oliver, S. (2017). *An introduction to systematic reviews*.

Hasannejadasl, H., Roumen, C., van der Poel, H., Vanneste, B., van Roermund, J., Aben, K., Kalendralis, P., Osong, B., Kiemeney, L., & Van Oort, I. (2021). Predicting erectile dysfunction after treatment for localized prostate cancer. *ArXiv Preprint ArXiv:2110.00615*.

Kim, N., Azadzoi, K. M., Goldstein, I., & De Tejada, I. S. (1991). A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth

muscle. *The Journal of Clinical Investigation*, *88*(1), 112–118.
Moreira-Soares, M., Coimbra, R., Rebelo, L., Carvalho, J., & DM Travasso, R. (2018). Angiogenic factors produced by hypoxic cells are a leading driver of anastomoses in sprouting angiogenesis–a computational study. *Scientific Reports*, *8*(1), 8726.
Nazari, A., Valizadeh, M. R., Hassanshahi, G., & Khorramdelazad, H. (2020). Expression of vascular endothelial growth factor and its receptors in infertile men with varicocele. *Journal of Reproductive Immunology*, *140*, 103131.
Nazir, F. S., Alem, M., Small, M., Con Nell, J. M. C., Lees, K. R., Walters, M. R., & Cleland, S. J. (2006). Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with Type 2 diabetes. *Diabetic Medicine*, *23*(4), 398–402.
Neves, D., Santos, J., Tomada, N., Almeida, H., & Vendeira, P. (2006). Aging and orchidectomy modulate expression of VEGF receptors (Flt-1 and Flk-1) on corpus cavernosum of the rat. *Annals of the New York Academy of Sciences*, *1067*(1), 164–172.
Orimoloye, O. A., Feldman, D. I., & Blaha, M. J. (2019). Erectile dysfunction links to cardiovascular disease—defining the clinical value. *Trends in Cardiovascular Medicine*, *29*(8), 458–465.
Papaioannou, D., Sutton, A., & Booth, A. (2016). Systematic approaches to a successful literature review. *Systematic Approaches to a Successful Literature Review*, 1–336.
Rajfer, J., Aronson, W. J., Bush, P. A., Dorey, F. J., & Ignarro, L. J. (1992). Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. *New England Journal of Medicine*, *326*(2), 90–94.
Ružić, A., Peršić, V., Miletić, B., Včev, A., Mirat, J., Soldo, I., Batinac, T., & Kovač, T. (2007). Erectile dysfunction after myocardial infarction–myth or a real problem? *Collegium Antropologicum*, *31*(1), 185–188.
Segura, A., Ballester, P., Ajo, R., Inda, M.-M., Urbano, A., Muriel, J., Ochando, I., Margarit, C., Martinez, E., & Peiró, A. M. (2019). Endothelial nitric oxide synthase gene polymorphisms and erectile dysfunction in chronic pain. *Gene*, *721*, 100005.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. *Journal of Business Research*, *104*, 333–339.
Sobrano Fais, R., Menezes da Costa, R., Carvalho Mendes, A., Mestriner, F., Comerma-Steffensen, S. G., Tostes, R. C., Simonsen, U., & Silva Carneiro, F. (2023). NLRP3 activation contributes to endothelin-1-induced erectile dysfunction. *Journal of Cellular and Molecular Medicine*, *27*(1), 1–14.
Sriram, K., Laughlin, J. G., Rangamani, P., & Tartakovsky, D. M. (2016). Shear-induced nitric oxide production by endothelial cells. *Biophysical Journal*, *111*(1), 208–221.
Symons, J. D., McMillin, S. L., Riehle, C., Tanner, J., Palionyte, M., Hillas, E., Jones, D., Cooksey, R. C., Birnbaum, M. J., & McClain, D. A. (2009). Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. *Circulation Research*, *104*(9), 1085–1094.
Tostes, R. C., Carneiro, F. S., Lee, A. J., Giachini, F. R. C., Leite, R., Osawa, Y., & Webb, R. C. (2008). Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation. *The Journal of Sexual Medicine*, *5*(6), 1284–1295.
Zhou, B., Trost, L. W., & Zhang, X. (2018). A Numerical Study of the Relationship Between Erectile Pressure and Shear Wave Speed of Corpus Cavernosa in Ultrasound Vibro-elastography. *ArXiv Preprint ArXiv:1806.00415*.
Zhu, D., Pham, Q. M., Wang, C., Colonnello, E., Yannas, D., Nguyen, B. H., Zhang, Y., Jannini, E. A., & Sansone, A. (2025). Erectile Dysfunction and Oxidative Stress: A Narrative Review. *International Journal of Molecular Sciences*, *26*(7), 3073.